CytomX Therapeutics
CTMX
126 hedge funds and large institutions have $422M invested in CytomX Therapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 34 reducing their positions, and 20 closing their positions.
70% more capital invested
Capital invested by funds: $249M → $422M (+$173M)
53% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 34
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
2.1% more ownership
Funds ownership: 82.21% → 84.31% (+2.1%)
0% more funds holding
Funds holding: 126 → 126 (0)
25% less call options, than puts
Call options by funds: $563K | Put options by funds: $746K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$49.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$27.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.7M |
| 4 |
BlackRock
New York
|
+$11M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$4.84M |
| 2 |
PA
Perceptive Advisors
New York
|
-$3.35M |
| 3 |
D.E. Shaw & Co
New York
|
-$2.35M |
| 4 |
Morgan Stanley
New York
|
-$2.3M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.87M |
CTMX Hedge Fund Activity: Q1 2021 in Review
126 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2021, worth a combined $422M — up 70% from $249M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CTMX positions and 20 closed out — a net gain of 2 holders — while 52 added to existing stakes and 34 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $49.2M. The largest seller was Renaissance Technologies, cutting an estimated $4.84M.
- 126 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $422M of CytomX Therapeutics stock for Q1 2021, up 70% quarter-over-quarter.
- 22 funds opened new CytomX Therapeutics positions in Q1 2021 and 20 closed out, a net change of +2 holders.
- The largest CytomX Therapeutics buyer in Q1 2021 was Point72 Asset Management, an estimated $49.2M added.
- The largest CytomX Therapeutics seller in Q1 2021 was Renaissance Technologies, an estimated $4.84M sold.
Based on aggregated 13F filings for Q1 2021.